As of 2026-03-16, the Fair Value of Helix Biopharma Corp (HBP.TO) is -0.38 CAD. This value is based on the Peter Lynch's Fair Value formula. With the current market price of 2.05 CAD, the upside of Helix Biopharma Corp is -118.46%.
With the market price of 2.05 CAD and our fair value calculation, Helix Biopharma Corp (HBP.TO) is not a good investment. Investing in HBP.TO stocks now will result in a potential loss of 118.46%.
Note: valuation result may not be accurate due to the company's negative EPS.
Peter Lynch's formula is:
The earnings growth rate we use in the formula is the average growth rate of net income/earnings over the last 5 years. If the average growth rate is smaller than 5%, we set it to 5%. If it is larger than 25%, we set it to 25%. If the TTM EPS is negative, Peter Lynch Fair Value's result can be unreliable.
| Historical Earnings | ||||||
| 2021-07-31 | 2022-07-31 | 2023-07-31 | 2024-07-31 | 2025-07-31 | 5Y Avg | |
| Net income | -8.04 | -6.56 | -6.29 | -9.26 | -5.20 | -7.07 |
| YoY growth | 10.59% | 18.34% | 4.17% | -47.28% | 43.81% | 5.93% |
| Market Cap (mil) | 156.58 |
| P/E | |
| Forward P/E |
| EPS | -0.06 |
| Avg earnings growth rate | 5.93% |
| TTM earnings | -4.88 |